In a new note to investors yesterday, an analyst has provided a rating update for the Healthcare company, Aphria Inc (TSXV: APH). Analyst Noel Atkinson from Clarus remains bullish on the stock.
Atkinson commented:
“We understand Aphria was able to obtain “exemptive relief” from the CSE in order to facilitate this transaction as a single event.”
Atkinson has an average return of 197.6% when recommending Aphria Inc.
According to TipRanks.com, Atkinson is ranked #117 out of 4875 analysts.
Read also: Here’s Why Arrowhead (ARWR) Skyrocketed Over 50% Today
Currently, the analyst consensus on Aphria Inc is a Moderate Buy with an average price target of C$24.50.
Aphria Inc’s market cap is currently C$4.49B and has a P/E ratio of 112.4. The company has a Price to Book ratio of 3.85.
Aphria, Inc. engages in the production and supply of medical marijuana. Its products include alien dawg, champlian indica, grower’s blend, champlain-sativa and blueberry. The company was founded by Cole Cacciavillani and John Cervini on June 22, 2011 and is headquartered in Leamington, Canada.
The company’s shares closed on Friday at C$20.41.
